Nymox Pharmaceutical Corporation (NYMX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.4350 |
| Open | 0.4203 |
| Bid | 0.4101 x 2200 |
| Ask | 0.4199 x 2200 |
| Day's Range | 0.3935 - 0.4600 |
| 52 Week Range | 0.3500 - 2.2700 |
| Volume | |
| Avg. Volume | 252,329 |
| Market Cap | 34.766M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings Date | May 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- Benzinga
Why Nymox Pharma Shares Sinking to 52-Week Low?
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has received a Refusal to File (RTF) letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymox's position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. In March, the company submitted a Fexapotide Triflutate application for benign prostatic hyperplasia (BPH). The letter referred to a new outstanding issue of longer-term safety data and indicate
- GlobeNewswire
NYMOX Receives RTF letter from FDA
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug Application (“NDA”) for Fexapotide Triflutate. Nymox’s position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. The letter referred to a new outstanding issue of longer-term sa
- GlobeNewswire
Nymox Announces Closing of $6.4 Million Financing
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of 3,878,789 common shares at a purchase price of $1.65 per share, sold pursuant to a registered direct offering. The Company has also issued to the investors, in a concurrent private placement, unregistered warrants to purch
